A recent study published in the renowned journal The Lancet shows that repetitive transcranial magnetic stimulation (rTMS) of the brain can help many people with therapy-resistant depression. In half of the people treated, the symptoms are significantly reduced, in one third they even disappear completely. The study thus confirms over 40 independent studies with over 2,000 patients worldwide. It also shows that the application of a newer form of rTMS can reduce the daily treatment time from more than half an hour to three minutes.
Effective and well-tolerated therapy option
rTMS is a non-invasive method of brain stimulation and is used to treat therapy-resistant depression. Magnetic impulses from the outside stimulate the frontal left brain lobe, which is involved in regulating the mood and is less active in depressed people. The great advantage of this method over other brain stimulation methods is that neither anaesthesia nor surgery is necessary and the frequent side effects of antidepressants are eliminated.
rTMS in Switzerland
Treatments with rTMS are performed by specialists in psychiatry or neurology. They are currently not yet reimbursed by the health insurance funds. The stimulators of the Danish manufacturer MagVenture are distributed in Switzerland by NEUROLITE, based in Belp (Berne). The company distributes and supports high-quality medical systems and products for hospitals and practices, which are mainly used in neurology and related areas, and ensures their support with a highly qualified team.
Life Science Communication supported NEUROLITE in its media relations. This continued the cooperation that began in 2016 with public relations work on the prevention and treatment of migraine.
